Search Results

You are looking at 71 - 80 of 136 items for :

  • "febrile neutropenia" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Z. Kidwai, Dwight D. Kloth, Eric H. Kraut, Gary H. Lyman, Sudipto Mukherjee, Lia E. Perez, Rachel P. Rosovsky, Vivek Roy, Hope S. Rugo, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, and Pamela S. Becker

resources page ( https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf ). 13 We have compiled the following in-depth description of the rationale and evidence supporting our recommendations. Avoidance and Treatment of Neutropenia Febrile neutropenia

Full access

Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Z. Kidwai, Dwight D. Kloth, Eric H. Kraut, Gary H. Lyman, Sudipto Mukherjee, Lia E. Perez, Rachel P. Rosovsky, Vivek Roy, Hope S. Rugo, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, and Pamela S. Becker

/HGF_COVID-19.pdf ). 13 We have compiled the following in-depth description of the rationale and evidence supporting our recommendations. Avoidance and Treatment of Neutropenia Febrile neutropenia (FN) is among the most common complications associated with

Full access

Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes, and Fernando Rivera

overall and grade 3/4 toxicities in comparison with doublets ( Table 3 ), particularly with more grade 3/4 anemia, stomatitis, febrile neutropenia (10.4% vs 6.5%), hepatic toxicity (15.8% vs 9.2%), and toxicity-related hospitalization (30.7% vs 22

Full access

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

-line FOLFIRINOX. After 38 weeks, imaging again showed progression of hepatic metastases. He received third-line therapy with docetaxel and irinotecan for 2 weeks, but this therapy was complicated by febrile neutropenia. A tumor specimen from the

Full access

Edmond Marzbani and Elihu Estey

, 6 patients were admitted for febrile neutropenia, and 3 cases of nonfatal Pneumocystis jiroveci were seen. 13 , 14 In a Japanese case series of 10 patients, a less-intensive regimen of ATRA, 6-MP, and MTX was used for maintenance, and no patients

Full access

Justine M. Kahn and Melissa Beauchemin

. Blood 2011 ; 117 : 2596 – 2603 . 10.1182/blood-2010-05-285379 21079154 32. Wright JD , Neugut AI , Ananth CV , Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes . JAMA Intern

Full access

Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer, and Maoko Naganuma

neutropenia (70%), thrombocytopenia (45%), anemia (18%), and febrile neutropenia (15%). 17 Lenalidomide was administered using different dosing schedules in these earlier studies. In one study, patients initially received lenalidomide at the 25-mg-daily dose

Full access

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

: implication and proposed mechanisms . World J Clin Oncol 2014 ; 5 : 272 – 282 . 10.5306/wjco.v5.i3.272 25114844 23. Kuderer NM , Dale DC , Crawford J , . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

Full access

Suzanne C. O'Neill, Claudine Isaacs, Calvin Chao, Huei-Ting Tsai, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo, and Arnold L. Potosky

. 38. Chia VM Page JH Rodriguez R . Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy . Breast Cancer Res Treat 2013 ; 138 : 621 – 631 . 39. Hall PS McCabe C

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead, and Rashmi Kumar

.6%) of febrile neutropenia in both arms. Overall survival data from this trial are immature. 24 NCCN Recommendations The NCCN Breast Cancer Panel has included the combination of palbociclib with letrozole as a first-line endocrine therapy option for